title: A challenging drug development process in the era of personalized medicine.
abstract: After years of hesitation a larger number of pharmaceutical and biotech companies are now supporting the idea of a more individualized pharmacotherapy. The companies that are now involved in this research-demanding area will have to face several challenges. The key factor for success will be an in-depth molecular understanding of the pathophysiology and the mechanism of the drug under development. The one-disease-one-drug-one-target paradigm that has been prevailing for decades is history. Most diseases are heterogeneous and based on molecular profiling they can be divided into biological subgroups that each requires a specific pharmacological intervention.
authors.affiliation: Dx-Rx Institute, Baunevaenget 76, DK-3480 Fredensborg, Denmark. jan.trost@dx-rx.dk
authors.forename: Jan Trøst
authors.initials: JT
authors.lastname: Jørgensen
mesh_terms: D015415:Biomarkers; D004194:Disease / Q000209:etiology / Q000235:genetics; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D025202:Molecular Diagnostic Techniques; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism; D057285:Precision Medicine / Q000379:methods*; D049490:Systems Biology
chemical_list: D015415:Biomarkers; D004364:Pharmaceutical Preparations